| Aug 16 |
Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance
|
| Aug 15 |
Arrowhead announces push into obesity space with two gene therapies
|
| Aug 14 |
Arrowhead Pharmaceuticals, Inc. (ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference (Transcript)
|
| Aug 14 |
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
|
| Aug 9 |
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2024 Earnings Call Transcript
|
| Aug 8 |
Arrowhead Research: Fiscal Q3 Earnings Snapshot
|
| Aug 8 |
Arrowhead Pharmaceuticals announces $500M strategic financing facility with Sixth Street
|
| Aug 8 |
Arrowhead Pharmaceuticals GAAP EPS of -$1.38 misses by $0.81
|
| Aug 8 |
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
|
| Aug 8 |
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
|
